Arizona Revised Statutes § 36-2228 Administration Of Opiate Antagonists; Training; Immunity; Designation By Director

36-2228. Administration of opiate antagonists; training; immunity; designation by director

A. Pursuant to a standing order issued by a physician licensed pursuant to title 32, chapter 13 or 17 or a nurse practitioner licensed pursuant to title 32, chapter 15 and authorized by law to prescribe drugs, an emergency medical care technician or a peace officer who is trained in the administration of naloxone hydrochloride or any other opiate antagonist that is approved by the United States food and drug administration and designated by the director may administer naloxone hydrochloride or another opiate antagonist to a person who the emergency medical care technician or peace officer believes is suffering from an opiate-related drug overdose.

B. The department, in coordination with the Arizona peace officer standards and training board, shall develop a training module for emergency medical care technicians and peace officers that provides training regarding the identification of a person suffering from an opiate-related drug overdose and the use of naloxone hydrochloride or other opiate antagonists.

C. Physicians who are licensed pursuant to title 32, chapter 13 or 17 and who issue a standing order, nurse practitioners who are licensed pursuant to title 32, chapter 15 and authorized by law to prescribe drugs and who issue a standing order and emergency medical care technicians and peace officers who administer naloxone hydrochloride or any other opiate antagonist pursuant to this section are immune from professional liability and criminal prosecution for any decision made, act or omission or injury that results from that act if those persons act with reasonable care and in good faith, except in cases of wanton or wilful neglect. This section does not create a duty to act or standard of care for peace officers to administer an opiate antagonist.

D. The director shall designate opiate antagonists that may be used pursuant to this section based on an evaluation of the opiate antagonist's safety and efficacy.

Section: Previous  36-2221  36-2222  36-2223  36-2224  36-2225  36-2226  36-2227  36-2228  36-2232  36-2233  36-2234  36-2235  36-2236  36-2237  36-2238  Next

Last modified: October 13, 2016